Get started
Author

Justin Moser

Observed name: J. Moser
ORCID: 0000-0002-0643-6759
Observed ORCID: 0000-0002-0643-6759
OpenAlex ID: A5027673468
Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer
2025 · Rebecca Porter, Bruno Bockorny, et al. · Journal for ImmunoTherapy of Cancer · 6
PDF
747P Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors
2022 · G.S. Falchook, S. Fu, et al. · Annals of Oncology · 4
PDF
1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
2024 · M.O. Butler, R. Weight, et al. · Annals of Oncology · 3
PDF
0828 Primary vulvar mucosal melanoma in a patient with Li-Fraumeni syndrome: A rare case report
2026 · A. Chandrasekaran, D. Baltazar, et al. · Journal of Investigative Dermatology
Abstract 7695: Blood-based proteomics analysis for uveal melanoma prognosis
2026 · Abarajithan Chandrasekaran, Nikhil Nayee, et al. · Cancer Research
SUPRAME: A Phase 3 trial evaluating anzutresgene autoleucel (anzu-cel, IMA203) PRAME-directed T-cell receptor T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma
2026 · A. Betof, M. Jalving, et al. · EJC Skin Cancer
PDF
Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic Melanoma
2026 · L. Karapetyan, J. Moser, et al. · EJC Skin Cancer
Works count: 7
Citation count: 13
H-index: 3
I10-index:
Year
Topic
Type